Evidence map›Paper›PMID 40511070›Full record

ReviewJournal of pharmacy & bioallied sciences2025

Prospective Evaluation of Screening Performance of First-Trimester Prediction Models for Preterm Preeclampsia.

Hussam Zain

Abstract readReview
In one paragraph

Review in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The Role of Angiogenetic Factors in Preeclampsia.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hussam ZainDepartment of Obstetric and Gynecology, College of Medicine, Majmaah University, Majmaah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preterm preeclampsia (PPE) is a serious pregnancy complication with significant risks for maternal and fetal health. This review aims to evaluate the prospective performance of first-trimester prediction models for PPE, highlighting their effectiveness, limitations, and clinical applicability. A comprehensive narrative review of studies published from 2020 to 2024 was conducted. Studies focusing on first-trimester prediction models for PPE were included, with an emphasis on their sensitivity, specificity, predictive values, and performance across different populations. The review revealed that multifactorial models combining biomarkers (e.g., pregnancy-associated plasma protein-A (PAPP-A), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1)), clinical risk factors, and ultrasound markers (e.g., uterine artery Doppler, mean arterial pressure (MAP)) show promising results with high sensitivity and specificity in predicting PPE. It is concluded that first-trimester prediction models for PPE are effective tools for early risk assessment but require further refinement and validation in diverse populations. Continued research and technological advancements, including machine learning and artificial intelligence (AI), are necessary to enhance the models' accuracy and generalizability for widespread clinical use.

Indexed as

Biomarkersfirst-trimester screeningmachine learningprediction modelspreterm preeclampsiasensitivityspecificityultrasound

Identifiers

PMID40511070
PMCPMC12156731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.